Contact this trialFirst, we need to learn more about you.
PD-L1 Inhibitor
NT-I7 + Atezolizumab for High-Risk Skin Cancer
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing whether adding NT-I7 to atezolizumab helps patients with high-risk melanoma, MCC, or cSCC who haven't responded to anti-PD-1/PD-L1 treatment or who have relapsed.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service